Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
| ▸ | METAP1 | P53582 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2416189 | 0.75 | NR3C1 (0.38) | MEN1KMT2ANPC1RAB9ANR3C1 | |
| SCHEMBL1458946 | 0.72 | KMT2A (0.46) | MEN1KMT2ANPC1RAB9ANR3C1 | |
| SCHEMBL662298 | 0.72 | NR1H2 (0.41) | MEN1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL17439469 | 0.72 | KMT2A (0.46) | MEN1KMT2ALMNAALOX5CYP2D6 | |
| SCHEMBL662586 | 0.72 | CYP2D6 (0.43) | MEN1KMT2ANPC1RAB9ANR3C1 | |
| SCHEMBL15676591 | 0.72 | CYP1A2 (0.56) | MEN1KMT2ANPC1RAB9ANR3C1 | |
| SCHEMBL8633925 | 0.71 | NPC1 (0.39) | MEN1KMT2ANPC1RAB9ANR3C1 | |
| SCHEMBL666600 | 0.69 | KMT2A (0.39) | MEN1KMT2ANPC1RAB9ANR3C1 | |
| SCHEMBL666273 | 0.69 | RAB9A (0.38) | MEN1KMT2ANPC1RAB9ANR3C1 | |
| SCHEMBL667451 | 0.69 | KMT2A (0.38) | MEN1KMT2ANR3C1LMNANR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | EUROSCREEN S.A. (BE) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | CPT1A, LIPC, PC | MEN1 1084/4885KMT2A 3648/4885NPC1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.